Pfizer intends to launch Inflectra (infliximab biosimilar) in the US in November 2016.

Pfizer plans to launch Inflectra (infliximab biosimilar) in the US in November 2016 at a 15% discount to Remicade. A patent infringement case was brought by Johnson and Johnson which was recently lost in the US District Court but is now subject to a Johnson and Johnson appeal. The effect of the introduction of Inflectra/Remsima on Remicade in Europe, where the drug is sold by Merck Inc., was a 26% decrease in sales so far.